From: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
 | Tumor classification (+: yes/-: no) | Tumor response |  | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | ER/PR | HER2 | Ki67 | Neoadjuvant | All | pCR no | pCR yes |  | |||
 |  |  |  | trastuzumab | N | % | n | % | n | % | P |
Hormone receptor-positive | + | - | + | NA | 176 | 100 | 162 | 92.0 | 14 | 8.0 | 0.05 |
 | + | - | - | NA | 140 | 100 | 136 | 97.1 | 4 | 2.9 |  |
 | + or - | + | + | + or - | 88 | 100 | 49 | 55.7 | 39 | 44.3 | 0.03 |
 | + or - | + | - | + or - | 14 | 100 | 12 | 85.7 | 2 | 14.3 |  |
HER2-positive | + or - | + | + or - | + | 50 | 100 | 24 | 48.0 | 26 | 52.0 | 0.03 |
 | + or - | + | + or - | - | 52 | 100 | 37 | 71.2 | 15 | 28.8 |  |
Triple negative | - | - | + | NA | 122 | 100 | 62 | 50.8 | 60 | 49.2 | 0.12 |
 | - | - | - | NA | 7 | 100 | 6 | 85.7 | 1 | 14.3 |  |
All | + or - | + or - | + or - | + or - | 547 | 100 | 427 | 78.1 | 120 | 21.9 | Â |